There was a relatively increased risk of hypoglycemia by 49% with SGLT2 inhibitors compared to placebo yet did not reach statistical significance (RR: 1.49, 95% CI: 0.86–2.58, p = 0.79, I2 = 0%) (Figure 11). This evidence concerns the gene SLC5A2 and Hypoglycemia.